Moderna Inc. (NASDAQ:MRNA) saw a downside of -11.37% to close Friday at $341.09 after subtracting -$43.77 on the day. The 5-day average trading volume is 16,932,660 shares of the company’s common stock. It has gained $434.00 in the past week and touched a new high 1 time within the past 5 days. An average of 14,931,065 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 18,019,965.
MRNA’s 1-month performance is -12.53% or -$48.85 on its low of $323.41 reached on 10/01/21. The company’s shares have touched a 52-week low of $65.49 and high of $497.49, with the stock’s rally to the 52-week high happening on 08/10/21. YTD, MRNA has achieved 226.50% or $236.62 and has reached a new high 34 times. However, the current price is down -31.44%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Sep 30, 4 days have gone by since the last insider trading activity for Moderna Inc. (MRNA). Bancel Stephane (Chief Executive Officer) most recently sold 10,000 shares at $381.82 per share on Sep 30. This transaction cost the insider $3,818,200. Chief Executive Officer, Bancel Stephane, sold 9,000 shares at a price of $393.44 on Sep 29. Then, on Sep 29, See remarks Andres Juan sold 5,000 shares at a price of $393.44 per share. This transaction amounted to $1,967,200.
The company’s PE ratio for the last five years has touched a high of 187.57 and a low of 27.67. MRNA stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 22.13 while the price-to-book (PB) in the most recent quarter is 20.45, with the price to cash flow ratio at 17.10.
Moderna Inc.’s quick ratio for the period ended June 29 was 1.20, with the current ratio over the same period at 1.20 meaning that MRNA stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.05, while the total debt to equity was 0.07. In terms of profitability, the gross margin trailing 12 months is 86.50%The trailing 12-month EBITDA margin is -91.10% while for the period ending June 29; Moderna Inc.’s operating margin was 54.40%. The firm’s gross profit as reported stood at $795.46 million against revenue of $803.39 million.
For the quarterly period ending June 29 this year, Moderna Inc.’s cash and short-term investments amounted to $2.39 billion against total debt of $603.0 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected MRNA to announce $5.95 per share in earnings in its latest quarter, but it posted $6.46, representing a 8.60% surprise. EBITDA for the quarter stood at more than $3.14 billion. MRNA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 9.45 billion, with total debt at $603.0 million. Shareholders hold equity totaling $403.65 million
Let’s look briefly at Moderna Inc. (MRNA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 26.44% to suggest the stock is trending oversold, with historical volatility in this time period at 74.40%.
The stock’s 5-day moving average is $379.58, reflecting a -20.70% or -$89.05 change from its current price. MRNA is currently trading -14.23% above its 20-day SMA, +114.54% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +5.44% and +131.69% respectively.
Stochastic %K and %D was 9.35% and 7.62% and the average true range (ATR) pointed at 27.43. The RSI (14) points at 34.98%, while the 14-day stochastic is at 13.09% with the period’s ATR at 26.67. The stock’s 9-day MACD Oscillator is pointing at -38.09 and -46.97 on the 14-day charts.
In the most recent analyst report for Moderna Inc. (NASDAQ: MRNA), Piper Sandler downgraded it to a Neutral rating. They previously had an Overweight rating on the stock. Analysts offering their rating for MRNA stock have a consensus rating for the stock as Hold. Currently, 3 brokerage advisors rate MRNA as a “sell,”, while 7 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 5 have offered a “buy” rating.
What is MRNA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $85.00 and a high of $485.00, with their median price target at $453.00. Looking at these predictions, the average price target given by analysts is for Moderna Inc. (MRNA) stock is $351.40.